[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"spinal-cord-injury\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:spinal-cord-injury":27},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,137,0,25,[9,54,78,105,132,164,185,209,290,329,355,380,405,432,456,478,510,538,562,587,613,638,658,686,708],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":33,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100643017","early-phase-1-coupled-gentamicin-lactobacillus-rhamnosus-in-nlutd-100643017",false,"NCT07643974","Coupled Gentamicin-Lactobacillus Rhamnosus in NLUTD","Effect of Dose Timing of Coupled Intravesical Gentamicin and Lactobacillus Rhamnosus LGG on Success and Length of Colonization in Men and Women With SCI\u002FD and NLUTD","Inclusion Criteria:\n\n* Neurologic diagnosis\n* ≥18 years old\n* Neurogenic bladder for at least 6 months\n* No USQNB-IC A, B1, or B2 symptoms\n* No currently diagnosed UTI (within 24 hours of initiating instillations)\n* Community dwelling (not in acute hospital setting)\n\nExclusion Criteria:\n\n* Known genitourinary pathology beyond NLUTD (i.e. kidney stones, bladder stones, vesicoureteral reflux, etc.)\n* Use of prophylactic antibiotics or any antibiotics within 2 weeks of beginning instillations\n* Instillation of intravesical agents other than saline bladder wash\n* Immunodeficiency\n* Psychologic or psychiatric conditions influencing the ability to follow instructions\n* Allergy to ampicillin, daptomycin, gentamicin\u002Fgentamycin, or probiotics\n* Participation in another study which could confound results","ALL","18 Years",{"count":20,"type":21},48,"ESTIMATED","INTERVENTIONAL",[24],"EARLY_PHASE1","The main objective of the proposed research study is to determine in men and women with spinal cord injury\u002Fdisease and neurogenic bladder whether the dose of coupled gentamicin \\& Lactobacillus rhamnosus GG affects the recolonization of the bladder, and whether the rate of success differs by sex. Secondary objectives include determining whether that recolonization lasts 7, 14, or 28 days; and safety of the coupled gentamicin \\& Lactobacillus instillations.",[27,28,29,30,31,32],"Spinal Cord Injury","Neurogenic Bladder (NB)","Neurogenic Lower Urinary Tract Dysfunction","Multiple Sclerosis","Spina Bifida","Urinary Tract Infection(UTI)",[34,35,36,37,38,39,40],"gentamicin","gentamycin","lactobacillus","spinal cord injury","spinal cord disease","urinary tract infection","neurogenic bladder","NOT_YET_RECRUITING","2026-08-20",{"date":44,"type":45},"2026-08-21","ACTUAL",{"date":47,"type":21},"2026-08",{"date":49,"type":21},"2027-09",{"name":51,"class":52},"Medstar Health Research Institute","OTHER",2,{"id":55,"slug":56,"hasResults":12,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":4,"eligibilityCriteria":60,"healthyVolunteers":12,"sex":17,"minAge":61,"maxAge":4,"enrollmentInfo":62,"targetDuration":4,"studyType":22,"phases":64,"briefSummary":66,"conditions":67,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":75,"locationsCount":77},"100609392","vibrant-capsule-for-spinal-cord-injury-neurogenic-bowel-dysfunction-100609392","NCT07213986","Vibrant Capsule for Spinal Cord Injury Neurogenic Bowel Dysfunction","Pilot Trial of the Vibrant Capsule for Spinal Cord Injury Neurogenic Bowel Dysfunction","Inclusion Criteria:\n\n* Individuals with chronic spinal cord injury (SCI) of more than one year.\n* Stable neurological level and function of SCI for at least six months.\n* Consistent bowel program without changes for at least 3 months.\n* At least one scheduled bowel movement (BM) every three days.\n* Use of digital stimulation, suppositories, enemas, or mini enemas, as part of the scheduled bowel program.\n* Use of oral medications as part of the bowel program.\n\nExclusion Criteria:\n\n* Bowel incontinence occurring more than once per week.\n* Non-English-speaking individuals.\n* History of bowel obstruction, ileus, diverticulitis, or bowel surgery for a disease (appendix removal is ok).\n* Persistent autonomic dysreflexia (AD) triggered by bowel movements.\n* Recent changes to spasticity medications within the past month.\n* History of significant gastrointestinal disorders\n* History of Zenker's diverticulum\n* Dysphagia\n* Esophageal stricture\n* Eosinophilic esophagitis or achalasia\n* Pregnancy.\n* Presence of implanted devices that could be affected by proximity to a direct current magnetic field.","21 Years",{"count":63,"type":21},12,[65],"NA","The goal of this study is to test the safety and effectiveness of Vibrant capsules in spinal cord injury patients with neurogenic bowel.",[68,27],"Neurogenic Bowel Dysfunction","RECRUITING","2026-08-19",{"date":44,"type":45},{"date":73,"type":45},"2026-01-06",{"date":70,"type":21},{"name":76,"class":52},"The University of Texas Health Science Center, Houston",1,{"id":79,"slug":80,"hasResults":12,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":22,"phases":87,"briefSummary":88,"conditions":89,"keywords":91,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":77},"100626074","empowerment-program-to-reduce-treatment-of-asymptomatic-bacteriuria-in-veterans-with-spinal-cord-injury-100626074","NCT07430904","Empowerment Program to Reduce Treatment of Asymptomatic Bacteriuria in Veterans With Spinal Cord Injury","Direct to Consumer Empowerment Program to Reduce Treatment of Asymptomatic Bacteriuria in Veterans With Spinal Cord Injury and Neurogenic Bladder","Inclusion Criteria:\n\n* Veterans with SCI\u002FD and neurogenic bladders who have been treated for at least one UTI in the past year\n* Have access to a telephone\n* Have not been involved in the development phase of the program\n\nExclusion Criteria:\n\n* Non-Veterans\n* Veterans without SCI\u002FD or neurogenic bladder\n* Patients with dementia who would not be able to provide consent or respond to interview prompts\n* Patients who do not receive primary care at the MEDVAMC\n* Veterans who participated in the development of the empowerment program",{"count":86,"type":21},30,[65],"Antimicrobial resistance is a major public health concern that worsens healthcare outcomes. Antibiotic resistant organisms occur more often in Veterans with spinal cord injury or disease (SCI\u002FD) given their frequent exposure to antibiotics, recurrent hospitalizations, and common use of urinary catheter devices. Veterans with SCI\u002FD are also at risk for overtreatment with antibiotics when they do not need them, particularly for over-diagnosed urinary tract infections. The investigators plan to create a patient empowerment program with input of Veterans with SCI\u002FD \\[and their providers\\] to help guide their decisions and next steps when they have a change in bladder symptoms. The program will give Veterans with SCI\u002FD the tools to speak up to their provider and advocate for themselves to avoid receiving unnecessary antibiotics. This program is highly innovative, as it puts Veterans with SCI\u002FD in charge of thoughtful antibiotic use, or antibiotic stewardship.",[27,90],"Spinal Cord Disease",[92,93,94,27,90,95],"Asymptomatic Bacteriuria","Antimicrobial Stewardship","Veteran Healthcare","Neurogenic Bladder","2026-08-17",{"date":70,"type":45},{"date":99,"type":21},"2027-08-02",{"date":101,"type":21},"2032-06-30",{"name":103,"class":104},"VA Office of Research and Development","FED",{"id":106,"slug":107,"hasResults":12,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":113,"sex":114,"minAge":18,"maxAge":115,"enrollmentInfo":116,"targetDuration":4,"studyType":118,"phases":4,"briefSummary":119,"conditions":120,"keywords":121,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":77},"100168574","male-fertility-program-100168574","NCT01467869","Male Fertility Program","The Miami Project Male Fertility Program","MFP","Inclusion Criteria:\n\n* Any man with spinal cord injury over the age of 18. Control Subjects will be any healthy man over the age of 18 with no recent history of infertility\n\nExclusion Criteria:\n\n* Women will be excluded.",true,"MALE","50 Years",{"count":117,"type":21},100,"OBSERVATIONAL","Following spinal cord injury, most men are infertile and require medical assistance to father children. The conditions that contribute to their infertility are erectile dysfunction, ejaculatory dysfunction, and semen abnormalities. The Miami Project Male Fertility Program is a research study designed to understand and improve impairments to male fertility resulting from spinal cord injury.",[27],[122,123],"abnormal semen","assisted conception","2026-08-12",{"date":96,"type":45},{"date":127,"type":45},"1991-01",{"date":129,"type":21},"2040-12",{"name":131,"class":52},"University of Miami",{"id":133,"slug":134,"hasResults":12,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":138,"eligibilityCriteria":139,"healthyVolunteers":12,"sex":17,"minAge":140,"maxAge":4,"enrollmentInfo":141,"targetDuration":4,"studyType":22,"phases":142,"briefSummary":145,"conditions":146,"keywords":149,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":160,"leadSponsor":162,"locationsCount":77},"100612277","psilocybin-to-treat-depression-in-spinal-cord-injury-100612277","NCT07251491","Psilocybin to Treat Depression in Spinal Cord Injury","Safety, Tolerability, Outcomes of Psilocybin for Depression (STOP Depression) in Veterans With Spinal Cord Injury","STOP","Inclusion Criteria:\n\n* Able and willing to provide informed consent\n* Spinal cord injury for at least 1 year\n* Confirmed diagnosis of depression\n* At least 22 years of age at time of consent\n* At least 50 kg (110 lbs.) body weight\n* Fully independent from ventilatory support (ventilator or diaphragm pacer)\n* Fluent in speaking and reading English\n* Able to swallow pills\n* Agree to have study visits recorded with audio and video\n* Agree to release outside medical and psychiatric records\n* Able and willing to taper off antidepressant, under clinician supervision\n* Agree to use adequate contraceptive methods\n\nExclusion Criteria:\n\n* Are not able to give adequate informed consent\n* Have used psilocybin or another psychedelic within 6 months\n* Have received Electroconvulsive Therapy (ECT) within 12 weeks\n* Have used ketamine within 12 weeks\n* Have a history of Bipolar I Disorder\n* Have a current eating disorder\n* Have a current severe alcohol or cannabis use disorder within the 6 months\n* Have an illicit drug or prescription drug substance use disorder within 12 months\n* Current serious suicide risk\n* History of heart attack, aneurysm, or stroke\n* Uncontrolled hypertension\n* Are pregnant or nursing","22 Years",{"count":86,"type":21},[143,144],"PHASE1","PHASE2","The main goal of this study is to determine if psilocybin is safe for use in people with SCI. The study will measure how people with SCI respond to three psilocybin doses: low (5mg), medium (10mg), and high (25mg).\n\nThe main question the study aims to answer is: does psilocybin increase the number and severity of adverse (bad) events reported by people with SCI? These may include pain, muscle spasms, symptoms of depression, and symptoms of low or high blood pressure. The investigators will also measure how well people with SCI tolerate the psychedelic experience, and compare responses between the low (5mg), medium (10mg), and high (25mg) doses.\n\nParticipants will:\n\n* Agree to be enrolled in the study for up to 13 months.\n* Agree to complete the seven (7) visits that are included in the psilocybin-assisted therapy.\n* Agree to complete follow-up study visits, including in-person visits to the James J Peters VA Medical Center, located in the Bronx, New York and remote visits.\n* Agree to keep a log of how they are feeling and any change in the frequency or severity of adverse events.",[27,147,148],"Depression - Major Depressive Disorder","Veteran",[150,151,152,153,154,155],"Tetraplegia","Paraplegia","Psychosocial Wellbeing","Depression","Neuropathic Pain","Psychedelics","2026-08-06",{"date":158,"type":45},"2026-08-10",{"date":156,"type":45},{"date":161,"type":21},"2028-03-01",{"name":163,"class":104},"James J. Peters Veterans Affairs Medical Center",{"id":165,"slug":166,"hasResults":12,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":4,"eligibilityCriteria":170,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":171,"targetDuration":4,"studyType":22,"phases":173,"briefSummary":174,"conditions":175,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":179,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":77},"100430638","exciflex-electroceutical-banadage-for-chronic-wound-therapy-100430638","NCT04887688","Exciflex Electroceutical Banadage for Chronic Wound Therapy","Toward Smart Personalized Electrotherapy for Enhanced Healing of Chronic Wounds","Inclusion Criteria:\n\n* All participants with chronic wounds treated at LSCVAMC will be potentially eligible for the study\n* Primary target populations will include Veterans with SCI who are inpatients or residents of the on-site Long-Term Care Unit and Veterans with diabetes being followed by the Podiatry Service for wound care\n\nExclusion Criteria:\n\nIn addition to meeting the general inclusion criteria noted above, further exclusion criteria relating to clinical factors include:\n\n* Pregnancy",{"count":172,"type":21},16,[65],"Objectives: The study objective is to carry a pilot clinical assessment comparing the exciflex bandage to standard of care (SoC) for ischemic wounds and will involve participants who are Veterans with lower extremity ischemic wounds.\n\nResearch Plan: The study will employ a randomized repeated measures design to assess the therapeutic effectiveness of exciflex in clinical use.\n\nMethodology: All participants with chronic ischemic wounds treated at Louis Stokes Cleveland VA Medical Center (LSCDVAMC) will be potentially eligible for the study. Primary target populations will include Veterans with SCI who are inpatients or residents of the on-site Long Term Care Unit and Veterans with diabetes being followed by the Podiatry Service for wound care. In addition to meeting the general inclusion criteria noted above, further exclusion criteria relating to clinical factors include; (1) Age less than 18 years and (2) Pregnancy.\n\nClinical Significance: Chronic ischemic wounds fail to heal normally and are a major challenge in the long-term care of many Veterans. The exciflex bandage can improve outcomes and lower cost by automatically delivering electrotherapy without disturbing the wound dressing for up to seven days, unless indicated. The overall study goal is to complete pre-market testing and evaluation of the exciflex bandage system.",[176,177,27,178],"Chronic Wound","Diabetes","Ischemic Wound",{"date":158,"type":45},{"date":181,"type":45},"2022-10-05",{"date":183,"type":21},"2029-09-30",{"name":103,"class":104},{"id":186,"slug":187,"hasResults":12,"nctId":188,"briefTitle":189,"officialTitle":189,"acronym":190,"eligibilityCriteria":191,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":192,"targetDuration":4,"studyType":22,"phases":193,"briefSummary":194,"conditions":195,"keywords":196,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":77},"100650196","valse-integration-of-neuromodulation-and-exoskeleton-systems-for-mobility-in-individuals-with-chronic-spinal-cord-injury-100650196","NCT07745686","VALSE: Integration of Neuromodulation and Exoskeleton Systems for Mobility in Individuals With Chronic Spinal Cord Injury","VALSE","Inclusion Criteria:\n\n* Currently enrolled participants who have completed the relevant phase of their parent study at CHUV: BoxSwitch (NCT05942339, after the optimisation phase), Think2Go (NCT06243952, after the rehabilitation phase, or STIMO-BSI (NCT04632290, after the calibration and training phase of the optional extension with system upgrade),\n* Must have a functional neuromodulation system,\n* Must be at least 18 years old,\n* Must be suffering from non-progressive traumatic spinal cord injury, sustained at least 12 months before signing the consent form,\n* Must weigh less than 100 kg,\n* Must have a standing height between 160 and 190 cm,\n* Must be able to grasp and lift bilateral crutches in a seated position,\n* Must have stable medical, physical and psychological condition as considered by the investigator,\n* Must be able to understand and interact with the study team in French or English,\n* Must agree to comply in good faith with all conditions of the study and to attend all scheduled appointments,\n* Must provide Informed Consent as documented by signature prior to any study-related procedures.\n\nExclusion Criteria:\n\n* Must not be diagnosed with severe osteoporosis\u002Fpenia:\n\nDual Energy X-ray Absorptiometry (DEXA) results indicating a t-score below -3.5 at either the femoral neck or the total proximal femur.\n\nDual Energy X-ray Absorptiometry (DEXA) results indicating a bone mineral density (BMD) \\\u003C 0.60 gm\u002Fcm2 at any knee region (distal femur, proximal tibia)\n\n* Must not have deep vein thrombosis in lower extremities within the past 6 months.\n* Must not have experienced lower extremity fractures within the last two years.\n* Must not have current pressure ulcer of the arms, trunk, pelvic area, or lower extremities\n* Must not present with a flexion contracture \\>15° at the hip or knee\n* Must not have severe concurrent medical conditions that contraindicate moderate to intense exercise (e.g., uncontrolled hypertension, coronary artery disease, congestive heart failure).\n* Must not have heterotopic ossification that impairs joint mobility\n* Must not be implanted with a life-supporting medical device (devices implanted in the parent study are not considered life-supporting),\n* Must not be pregnant,\n* Must not be the investigator himself, his\u002Fher family members, employees, or other dependent persons.",{"count":63,"type":21},[65],"The purpose of this clinical study is to evaluate the preliminary safety and feasibility of using the VALSE system, which combines spinal cord stimulation with the TWIICE robotic exoskeleton, to support motor recovery and reduce reliance on laboratory-based equipment during rehabilitation in participants with traumatic spinal cord injury. The TWIICE exoskeleton is integrated through the NR system, a platform developed by EPFL. The goal is to assess the clinical safety and practical application of this combined neuroprosthetic approach in a small number of participants, in order to guide future refinements of the device and protocol, support the development of scalable interventions integrating spinal stimulation with robotic assistance, and inform strategies for delivering rehabilitation in more accessible, real-world environments.",[27],[197,198,199],"exoskeleton","Spinal cord stimulation","Brain spine interface","2026-08-03",{"date":202,"type":45},"2026-08-04",{"date":204,"type":21},"2026-09-15",{"date":206,"type":21},"2028-09",{"name":208,"class":52},"Ecole Polytechnique Fédérale de Lausanne",{"id":210,"slug":211,"hasResults":12,"nctId":212,"briefTitle":213,"officialTitle":214,"acronym":215,"eligibilityCriteria":216,"healthyVolunteers":12,"sex":114,"minAge":18,"maxAge":4,"enrollmentInfo":217,"targetDuration":4,"studyType":22,"phases":219,"briefSummary":221,"conditions":222,"keywords":236,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":283,"startDateStruct":284,"completionDateStruct":286,"leadSponsor":288,"locationsCount":289},"100650026","phase-2-testosterone-therapy-with-or-without-finasteride-after-spinal-cord-injury-trt-sci-trial-100650026","NCT07742553","Testosterone Therapy With or Without Finasteride After Spinal Cord Injury: TRT-SCI Trial","A Multisite, Double-blind, Randomized Controlled Trial Comparing Body Composition, Muscle, and Bone Changes to TestosteRone Therapy With or Without Finasteride After Spinal Cord Injury: TRT-SCI Trial","TRT-SCI","Inclusion Criteria:\n\n* Veterans eligible for care within the Veterans Health Administration (VHA)\n* Diagnosis of motor incomplete SCI (AIS C-D) for \\>24-months involving spinal segment lumbar (L)1 or above from trauma, vascular, or orthopedic pathology\n* Low total testosterone (\\\u003C300 nanograms\u002Fdecilliter \\[ng\u002FdL\\]) and\u002For low free testosterone (\\\u003C4.6 ng\u002FdL)\n* Presence of one or more sign of low testosterone, defined as:\n\n  * decreased energy\n  * motivation\n  * initiative or self-confidence\n  * increased fatigue or tiredness\n  * reduced sexual desire or activity\n  * decreased spontaneous (e.g., morning) erections or erectile dysfunction\n  * loss of body hair or reduced shaving\n  * feeling sad or blue or having a depressed mood or a persistent low-grade depressive disorder (defined as a score of \\>3 on the Patient Health Questionnaire \\[PHQ\\]-2)\n  * hot flashes\n  * fatigue or irritability\n  * poor concentration or memory\n  * mild unexplained (normocytic-normochromic) anemia, defined as hematocrit (HCT) \\\u003C40%, hemoglobin \\\u003C13.6 grams\u002Fdeciliter (g\u002FdL), or red blood cell count \\\u003C4.5 million\u002Fmicroliter (mcL)\n  * sleep disturbances or increased sleepiness\n  * reduced muscle bulk, strength, or physical function\n  * increased body fat or body mass index\n* Presence of motor impairment, defined as self-selected walking pace ≤1.0 meters\u002Fsecond (m\u002Fs) on a 10-meter walk test (10mWT), with or without gait devices or braces and with or without assistance from another person, or as self-selected walking pace \\>1.0 m\u002Fs with reliance on a gait device or brace or with highly compensated movement impairment identified by a trained observer\n* Medically stable condition asymptomatic for bladder infection, major decubiti, cardiopulmonary disease, or other significant condition that will interfere with the study\n* Documented approval from a physician verifying medical status\n\nExclusion Criteria:\n\n* Involvement in another research study that may influence outcomes\n* Mental state that precludes understanding the protocol\n* Life expectancy \\\u003C12 months\n* History of or current congenital spinal cord injury (SCI) (e.g., Chiari malformation, myelomeningocele, intraspinal neoplasm, Friedreich's ataxia) or degenerative spinal disorder (e.g., spinocerebellar degeneration) that may complicate procedures\n* Amyotrophic lateral sclerosis, multiple sclerosis, or other neurologic injury \u002F impairment that may complicate procedures\n* Current cancer diagnosis\n* History of prostate or breast cancer\n* Any diagnosed or treated cancer in the past 24 months, except basal or squamous cell carcinoma of the skin that has been successfully treated\n* Any major lower-limb fracture in the past 12 months\n* Unevaluated circulating prostate-specific antigen (PSA) \\>4.0 nanograms\u002Fmilliliter (ng\u002FmL) or \\>3.0 ng\u002FmL in men with prostate cancer risk factors, including agent orange exposure, first degree relative with prostate cancer, or African American background\n* Currently seeking fertility or expected during the study\n* Diagnosed gynecomastia\n* Hematocrit (HCT) \\>48%\n* Any major cardiovascular event in the last 6 months, defined as:\n\n  * an acute myocardial infarction\n  * any cardiac revascularization procedure including stenting\n  * angioplasty or coronary artery bypass grafting\n  * revascularization of the carotid or middle cerebral artery or procedure to treat critical limb ischemia\n  * hospitalization due to unstable angina\n  * transient ischemic attack\n  * stroke\n  * peripheral vascular disease\n* Any angina that is not controlled on a current medical regimen (Canadian class II, III, or IV)\n* Poorly compensated congestive heart failure (New York Heart Association \\[NYHA\\] class III or IV)\n* Poorly controlled hypertension when on medication (consistent systolic BP ≥160 mmHg or diastolic BP ≥100 mmHg)\n* Poorly controlled arrhythmia of any type\n* Severe valvular heart disease\n* Baseline electrocardiogram findings such as left bundle branch block or marked abnormality that precludes serial screening for occult ischemic events\n* History of unprovoked deep venous thrombosis, unprovoked pulmonary embolism, history of recurrent deep venous thrombosis or known thrombophilia\n* Major non-cardiovascular surgery (e.g., major abdominal or thoracic procedure) within 90 days before screening or a major surgery scheduled at the time of screening\n* Liver enzymes (aspartate aminotransferase \\[AST\\] or alanine aminotransferase \\[ALT\\]) \\>1.5 times the normal upper limit\n* Severe or end-stage chronic kidney disease defined as eGFR \\\u003C30 milliliters\u002Fminute (mL\u002Fmin)\n* Diagnosed, but untreated severe obstructive sleep apnea\n* Use of an agent that alters sex-steroid metabolism in the past 90 days, such as: testosterone therapy (TRT), compounded or over-the-counter androgenic hormone or androgen precursor, 5-alpha reductase (5AR) inhibitors, growth hormone, clomiphene, aromatase inhibitors, anti-estrogen or estrogen treatment, or others\n* Use of anti-resorptive or bone anabolic drug therapy in the past 180 days\n* Acute use (\\>5 days) of any opioid (e.g., oxycodone, hydrocodone) or systemic glucocorticoids \\>7.5 milligrams (mg)\u002Fday prednisone equivalent (e.g., hydrocortisone 30 mg, methylprednisolone 6 mg, or dexamethasone 1.2 mg) in the week before screening, except for men who are taking these for a chronic condition and who are anticipated to continue these for the study duration\n* Known allergy to any TRT component (e.g., cottonseed oil or other)\n* Any other condition, lab abnormality, therapy, medical or psychiatric condition, or reason that might pose a risk to the participant, make participation not in the person's best interest, confound the study results (e.g., inability to comply with study requirements), make the participant unsuitable to receive a study intervention, or interfere with their ability to participate for the full study duration",{"count":218,"type":21},300,[144,220],"PHASE3","Spinal cord injury (SCI) results in lower limb muscle loss, bone loss, and high fat mass that impede the recovery of physical function, increase bone fracture risk, and worsen health and quality of life. These deficits result from reduced activity after SCI and may be worsened by low testosterone, which is present in many men with SCI. In older men with low testosterone who do not have SCI, testosterone therapy (TRT) is known to increase muscle mass, muscle strength, and bone mineral density, and to reduce body fat. However, it is not known if TRT is effective in men with SCI. The purposes of this study are to determine the effectiveness of TRT in men who have low testosterone and difficulty walking after chronic motor incomplete SCI and to assess whether a process in the body that changes testosterone to dihydrotestosterone (DHT; another hormone that is stronger than testosterone) impacts the effectiveness of TRT in the impaired lower limbs and in other tissues after SCI. The researchers hypothesize that TRT will improve muscle and bone in the impaired limbs of men with chronic incomplete SCI and reduce fat mass, and that finasteride (a drug that blocks that blocks a process that changes testosterone to DHT) will influence prostate symptoms but not the musculoskeletal or body composition benefits produced by TRT.",[27,223,224,225,226,227,228,229,230,231,232,233,234,235],"Spinal Cord Injuries","Injuries, Spinal Cord","Spinal Cord Contusion","Spinal Cord Trauma","Trauma, Nervous System","Wounds and Injuries","Spinal Cord Compression","Nervous System Diseases","Spinal Cord Diseases","Gonadal Disorders","Endocrine System Diseases","Hypogonadism","Genital Diseases, Male",[237,238,239,240,241,242,243,244,245,246,247,248,249,250,251,252,253,254,255,256,257,258,259,260,261,262,263,264,265,266,267,268,269,270,271,272,273,274,275,27,276,277,278,279,280,223,227,228,281,230,231,232,233,234,235,282],"Testosterone","Testosterone cypionate","Testosterone enanthate","Testosterone 17 beta-cypionate","Testosterone undecanoate","Methyltestosterone","Testosterone propionate","Dihydrotestosterone","Androgens","Hormones","Hormone Substitutes, and Hormone Antagonists","Physiologic Effects of Drugs","Pharmacologic Actions","Therapeutic Uses","Anabolic Agents","Testosterone Therapy","Testosterone Replacement Therapy","Dual Energy X ray Absorptiometry","Lean Tissue Mass","Body Composition","Lipid and Glucose profile","Muscle Strength","5-alpha Reductase","Muscle Mass","Bone Mineral Density","Adipose Tissue","Fat Mass","Body Fat","Density, Bone","Bone Formation","Bone Resorption","Bone Density Conservation Agents","Muscle, Skeletal","Bone and Bones","Gait","Walking","Locomotion","Motor Activity","Finasteride","Genital Diseases","Urogenital Diseases","Male Urogenital Diseases","Bone Diseases","Musculoskeletal Diseases","Central Nervous System Diseases","Steroids",{"date":202,"type":45},{"date":285,"type":21},"2027-10-01",{"date":287,"type":21},"2032-03-31",{"name":103,"class":104},4,{"id":291,"slug":292,"hasResults":12,"nctId":293,"briefTitle":294,"officialTitle":295,"acronym":296,"eligibilityCriteria":297,"healthyVolunteers":12,"sex":17,"minAge":298,"maxAge":4,"enrollmentInfo":299,"targetDuration":4,"studyType":22,"phases":301,"briefSummary":302,"conditions":303,"keywords":307,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":321,"lastUpdatePostDateStruct":322,"startDateStruct":323,"completionDateStruct":325,"leadSponsor":327,"locationsCount":77},"100621832","spinal-stimulation-with-gait-training-to-improve-lower-limbs-motor-recovery-in-spinal-cord-injury-100621832","NCT07375745","Spinal Stimulation With Gait Training to Improve Lower Limbs Motor Recovery in Spinal Cord Injury","Combined Gait Training and Transcutaneous Spinal Cord Stimulation to Enhance Lower Limbs Motor Recovery After Subacute SCI","CIMELocomotion","Inclusion Criteria:\n\n* paraplegic or quadriplegic participants with a subacute spinal cord injury (sSCI), defined as the stage of spinal cord damage occuring between 1 week and 6 months post-injury\n* above 16 years old\n* have a lesion between C1 - L2\n* be considered as AIS A to D\n* be able to stay at least 10 minutes standing with or without assistance\n* can provide informed consent (no cognitive deficits by MoCA)\n* be able to follow instructions in French or English\n\nExclusion Criteria:\n\n* pacemaker\n* active cancer on stimulation site or metastatic cancer\n* unhealed wound, scar or pain which makes positioning of the electrodes impossible\n* participants with specific contraindications to TMS (epilepsy, non-union cranial fracture and increased intracranial pressure) will be able to participate in the study, but will not receive TMS\n* chronic and severe neuropathic pain\n* pharmacology or implants that may impede with rehabilitation or spinal stimulation\n* pregnancy","16 Years",{"count":300,"type":21},40,[65],"Spinal cord injury (SCI) often results in partial or complete loss of movement. In the subacute phase (\\\u003C 6 months), the central nervous system shows increased potential for neuroplasticity, making it more responsive to rehabilitation and external stimulation. Standard care in rehabilitation centers relies on activity-based therapy (ABT), which uses intensive, task-specific training to promote recovery. Although ABT can improve mobility, its effects are often limited due to the nature of SCI and the indirect activation of neural circuits.\n\nRecent findings suggest that adding transcutaneous spinal cord stimulation (tSCS) to ABT in chronic SCI (\\> 12 months) can enhance lower-limb motor recovery. This study will evaluate whether combining tSCS with gait training is safe and feasible in individuals with subacute SCI and whether it improves lower-limb motor outcomes compared with gait training alone.\n\nThe investigators hypothesize that pairing gait training with tSCS early after injury will be safe and feasible and that tSCS delivered during gait training will augment leg muscle activation and lead to greater functional improvements. The study will also assess the feasibility, safety and tolerability of implementing this combined intervention in a intensive functional rehabilitation setting.",[27,304,273,305,306],"Spinal Cord Injury Subacute","Gait Disorder, Sensorimotor","Gait Disorders",[27,308,273,309,310,311,271,312,313,314,315,316,317,272,318,319,320],"Neuromodulation","tSCS","Non-invasive","Transcutaneous","Transcranial Magnetic Stimulation","Subacute","Artificial Intelligence","AI","Lower Limb","Gait training","Transcutaneous spinal stimulation","Tonic stimulation","Combined gait training and neuromodulation","2026-07-31",{"date":200,"type":45},{"date":324,"type":21},"2026-10-01",{"date":326,"type":21},"2029-07",{"name":328,"class":52},"Centre for Interdisciplinary Research in Rehabilitation of Greater Montreal",{"id":330,"slug":331,"hasResults":12,"nctId":332,"briefTitle":333,"officialTitle":334,"acronym":335,"eligibilityCriteria":336,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":337,"targetDuration":4,"studyType":22,"phases":339,"briefSummary":340,"conditions":341,"keywords":344,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":348,"lastUpdatePostDateStruct":349,"startDateStruct":350,"completionDateStruct":352,"leadSponsor":353,"locationsCount":77},"100649836","early-phase-1-neurorise-intrathecal-ce-1-treatment-for-traumatic-sci-100649836","NCT07739043","NeuroRise: Intrathecal CE-1 Treatment for Traumatic SCI","A Single-Arm and Open Labeled Clinical Study of CE1 (Allogeneic Umbilical Cord-Derived Mesenchymal Stem Cells, or UC-MSC) in Traumatic Spinal Cord Injury Patients Within Ten Years of Injury","NeuroRise","Inclusion Criteria:\n\n1. Once the voluntary nature of the study is explained in detail, the participant must be willing to provide written informed consent and complete HIPAA documentation before conducting any study-related procedure. A signed written informed consent and ability to comply with the study protocol according to International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) and local regulations is required.\n2. Male or female aged 18 years and older at the time of enrollment\n3. Females of childbearing potential must have a negative pregnancy test prior to receiving the study drug and will agree to use adequate contraception (hormonal\u002Fbarrier method or abstinence) from the time of screening to a period of 1 year following completion of the drug treatment cycle. Females of childbearing potential are defined as premenopausal and not surgically sterilized, or post-menopausal for fewer than two years. If the urine pregnancy test is positive, the study drug will not be administered, and the result will be confirmed by a serum β-hCG test. β-hCG tests will be performed at a central clinical laboratory, whereas urine pregnancy tests will be performed by qualified personnel using a kit.\n4. Females becoming pregnant during the study will continue to be monitored for the duration of the study or completion of the pregnancy, whichever is longer. Monitoring will include perinatal and neonatal outcomes. Any serious adverse events (SAE) associated with pregnancy will be recorded.\n5. SCI categorized as either complete (AIS grade A) or incomplete (AIS grade B, C or D) at the time of recruitment.\n6. Injuries located below the C2 level confirmed by MR imaging.\n7. SCI must be traumatic, blunt\u002Fnon-penetrating in nature, and not degenerative.\n8. Full understanding of the requirements of the study and willingness to comply with the treatment plan, laboratory tests, diagnostic imaging, complete physical and neurologic examination, and follow-up visits and assessments.\n9. Full understanding of the requirements of their rehabilitation program prescribed by physical and occupational therapists.\n10. Injury within 10 years before enrollment or screening period. Both acute and chronic SCI patients may be enrolled. Chronic SCI is defined as at least one year post-injury with stabilized neurological function.\n11. The participant must be able to tolerate intrathecal injections.\n12. The participant must have negative serology for HIV, VDRL, Hepatitis B and C\n13. Adequate vital organ function defined by normal laboratory values for creatinine, ALT, AST, total bilirubin, NT-ProBNP. If these labs are out of range, they must be reviewed by PI and confirmed. Rescreening can be done after treatment and retesting.\n14. Blood platelets count equal to or higher than 100,000 \u002FμL and INR level equal to or less than 1.5 must be encountered.\n\nExclusion Criteria:\n\n1. Pregnant or nursing, or planning on becoming pregnant during the study period\n2. SCI initially classified as AIS grade E at the time of injury\n3. SCI located above C2 level confirmed by magnetic resonance imaging (MRI).\n4. History of receiving MSC, gene or exosome therapy for any indications\n5. History of intra-spinal infection\n6. History of superficial infection in the index spinal level within 6 months of enrollment\n7. Evidence of current superficial infection affecting the index spinal level at the time of enrollment\n8. On chronic, immunosuppressive transplant therapy or having a chronic, immunosuppressive state, including chronic use of systemic steroids\u002Fcorticosteroids. Use of steroids\u002Fcorticosteroids in the acute SCI phase is permissible but the participant must have been off steroids for at least 14 days prior to the first injection and cannot take steroids for at least one month after injection.\n9. Taking anti-rheumatic disease medication (including methotrexate or other antimetabolites) within 3 months prior to study enrollment.\n10. Ongoing infectious disease, including but not limited to tuberculosis, HIV, hepatitis, and syphilis.\n11. Fever, defined as temperature above 99ºF\u002F37.2ºC or mental confusion at the time of IPA.\n12. Clinically significant cardiovascular (e.g., history of myocardial infarction, congestive heart failure or uncontrolled hypertension \\> 90 mmHg diastolic and\u002For 180 mmHg systolic), neurological (e.g., stroke, TIA) renal, hepatic or endocrine disease (e.g., diabetes, osteoporosis).\n13. History of malignancy including melanoma except for localized skin cancers (with no evidence of metastasis, significant invasion, or re-occurrence within three years of baseline). Any other malignancy will not be allowed. Provided they have not demonstrated clinical signs or symptoms of infection and have not required treatment, participants with large granular lymphocytic leukemia, upon consultation with their Hematologist\u002FOncologist, may be considered but should undergo additional testing at screening.\n14. History of blood dyscrasia, including but not limited to anemia, thrombocytopenia, and monoclonal gammopathy.\n15. History of bleeding disorders and actual levels of blood platelet lower than 100,000\u002FμL and\u002For INR equal to or higher than 1.5.\n16. History or presence of brain injury, hydrocephalus, meningitis, cerebral palsy, altered consciousness, signs\u002Fsymptoms of neurodegenerative disorders (e.g., stroke, amyotrophic lateral sclerosis, multiple sclerosis, etc.), based on medical history and at the discretion of the investigator.\n17. Participation in a study of an experimental drug or medical device within 3 months of study enrollment\n18. Known allergy to local anesthetics of other components of the study drug.\n19. Any contraindication to MRI scan according to MRI guidelines, or unwillingness to undergo MRI procedures.\n20. History of or current evidence of alcohol or drug abuse or dependence, recreational use of an illicit drug or prescription medications, or use of medical marijuana within 28 days of study entry\n21. Diagnosis of schizophrenia or bipolar disorder\n22. Participants with untreated baseline depression, diagnosed by the Beck Depression Inventory, past medical history, and baseline assessment conducted by a psychologist or a psychiatrist. Participants with depression or anxiety disorders who are in remission or receiving treatment can be enrolled in the study.\n23. Any severe condition pre-existing before or after traumatic SCI at the discretion of the Principal Investigator (PI).",{"count":338,"type":21},8,[24],"The purpose of this study is to assess the safety and tolerability of intrathecal administration of CE-1 at a weight-based dose (cells\u002Fkg BW), capped at a maximum total dose of 1×10⁸ cells in 10 mL, with administered volume calculated using M = 0.167 mL\u002Fkg BW.\n\nStudy details include:\n\nThe overall study duration will be up to three years. The primary endpoint will be assessed at 6 months following investigational product administration. An additional secondary endpoint will be assessed at 12 months in the form of a phone call.\n\nStudy visits therefore consist of one interventional visit, an evaluation visit within two weeks post-injection, a primary endpoint follow-up visit at 6 months, and a secondary endpoint follow-up phone call at 12-months.",[342,343,27],"SCI - Spinal Cord Injury","SCI",[345,346,347],"Stem cells","Spinal cord injury","Mesenchymal stem cells","2026-07-28",{"date":321,"type":45},{"date":351,"type":21},"2026-09",{"date":49,"type":21},{"name":354,"class":52},"Cell Therapy LLC",{"id":356,"slug":357,"hasResults":12,"nctId":358,"briefTitle":359,"officialTitle":360,"acronym":4,"eligibilityCriteria":361,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":362,"enrollmentInfo":363,"targetDuration":4,"studyType":22,"phases":365,"briefSummary":366,"conditions":367,"keywords":369,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":348,"lastUpdatePostDateStruct":372,"startDateStruct":374,"completionDateStruct":376,"leadSponsor":378,"locationsCount":77},"100606766","motoneuron-recruitment-and-motor-evoked-potential-up-conditioning-mep-in-spinal-cord-injury-sci-100606766","NCT07179822","Motoneuron Recruitment and Motor Evoked Potential Up-Conditioning (MEP) in Spinal Cord Injury (SCI)","Can MEP Conditioning Improve Corticospinal Recruitment of Motoneurons in Chronic Cervical SCI?","Inclusion Criteria:\n\n* Adult (≥18 yrs old)\n* a history of injury to spinal cord at or above C6\n* neurologically stable (\\>1 year post SCI)\n* medical clearance to participate\n* weak wrist extension at least unilaterally\n* expectation that current medication will be maintained without change for at least 3 months.\n\n  * Stable use of anti-spasticity medication (e.g., baclofen, diazepam, tizanidine) is accepted. (Because only neurologically stable subjects will enter this study, medication changes will be unlikely.)\n  * In participants with bilateral wrist extension weakness in whom Extensor Carpi Radialis (ECR) MEP can be elicited in both arms, the more severely impaired arm is studied. In participants with unilateral wrist weakness or in participants with bilateral wrist weakness in whom an ECR MEP can be elicited in only one arm, that arm is studied.\n\nExclusion Criteria:\n\n* motoneuron injury\n* unstable medical condition\n* cognitive impairment (because the studied intervention is a learning-based intervention)\n* a history of epileptic seizures\n* a pre-existing or confounding neurological condition (e.g., history of MS, Stroke, Parkinson's disease)\n* metal implants in the cranium\n* implanted biomedical device in or above the chest (e.g., a cardiac pacemaker, cochlear implant)\n* no measurable MEP elicited in the ECR\n* inability to produce any voluntary ECR EMG activity\n* extensive use of functional electrical stimulation to the arm on a daily basis (as it may interfere with or augment the effects of MEP conditioning itself)\n* pregnancy (due to changes in posture and potential medical instability)\n* inability or unwillingness of subject or legal guardian\u002Frepresentative to give informed consent","80 Years",{"count":364,"type":21},15,[65],"The purpose of this research study is to examine the effect of a brain stimulation training to improve the function of brain-spinal cord- muscle connections. Because brain-to-muscle pathways are very important in our movement control, restoring function of these pathways may improve movement problems after injuries. Spinal cord injury causes damage to the brain-to-muscle connection. However, when the injury is \"incomplete\", there is a possibility that some of the brain-to-muscle pathways are still connected and may be trained to improve movement function. For examining brain-to-muscle pathways, investigators use a transcranial magnetic stimulator. Investigators hope that the results of this research study will help us develop new treatments for people who have movement disabilities. This study will require about 42 visits over the first 14 weeks, and another 6 visits over an additional 3 months. Each visit will take about 1 ½ hours.",[368,27],"Spinal Cord Injuries and Disorders (SCI\u002FD)",[370,371],"Movement Disorders","Rehabilitation Studies",{"date":373,"type":45},"2026-07-29",{"date":375,"type":45},"2025-11-03",{"date":377,"type":21},"2027-09-30",{"name":379,"class":52},"Medical University of South Carolina",{"id":381,"slug":382,"hasResults":12,"nctId":383,"briefTitle":384,"officialTitle":384,"acronym":4,"eligibilityCriteria":385,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":386,"targetDuration":4,"studyType":22,"phases":388,"briefSummary":389,"conditions":390,"keywords":392,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":397,"lastUpdatePostDateStruct":398,"startDateStruct":399,"completionDateStruct":401,"leadSponsor":403,"locationsCount":77},"100649742","understanding-and-enhancing-human-health-and-movement-100649742","NCT07738978","Understanding and Enhancing Human Health and Movement","Inclusion Criteria:\n\n* Skeletal maturity and ability to sign informed consent (\\>18 years)\n* Non-ventilator dependent paralysis resulting from injuries such as: mid cervical\u002Fthoracic (C4 or below) spinal cord injuries, poststroke hemiparesis, TBI, or MS, affecting the trunk and\u002For lower limbs\n* Innervated and excitable lower extremity and trunk musculature\n* Adequate social support and stability\n* Willingness to comply with follow-up procedures\n* Time post injury greater than six months\n* Appropriate body habitus (height and weight within acceptable limits as determined by study physician)\n* Neurologically stable as determined by a physician\n\nExclusion Criteria:\n\n* Non-English speaking\n* Females who are pregnant\n* Current pressure injuries that would be exacerbated by study activities\n* Severe contractures or uncontrolled spasticity of any major joint of the upper or lower extremities that results in a fixed deformity that would interfere with study activities\n* History of spontaneous fractures or other evidence of excessively low bone density\n* History of vestibular dysfunction, balance problems, or spontaneous falls\n* Acute and or\u002Funtreated orthopedic problems that would prevent a participant from weight bearing or exercising such as a dislocation or fracture.\n* Acute and\u002For chronic problems left untreated or not controlled that would put a participant at risk by using stimulation such as cardiac abnormalities, immunological\u002Fpulmonary\u002Frenal\u002Fcirculatory compromise, diabetes or hypertension\n* Presence of a demand pacemaker or cardiac defibrillator\n* Any other medical or psychological condition that would be a contraindication\n* Current pressure ulcers\n* Significant range of motion limitations that would compromise study activities\n* Body habitus that would compromise study activities",{"count":387,"type":21},75,[65],"By doing this study, investigators hope to learn how electrical stimulation can improve human movement, biomechanics, and function and to gather information on the safety and effectiveness of an implanted electrical stimulation system after paralysis from spinal cord injury, stroke, multiple sclerosis, and traumatic brain injury.",[27,391,30],"Stroke (CVA) or Transient Ischemic Attack",[393,394,395,396],"paralysis","electrical stimulation","neuroprosthesis","implanted device","2026-07-27",{"date":321,"type":45},{"date":400,"type":45},"2021-03-21",{"date":402,"type":21},"2034-03-21",{"name":404,"class":104},"Louis Stokes VA Medical Center",{"id":406,"slug":407,"hasResults":12,"nctId":408,"briefTitle":409,"officialTitle":410,"acronym":4,"eligibilityCriteria":411,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":412,"targetDuration":4,"studyType":22,"phases":413,"briefSummary":414,"conditions":415,"keywords":416,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":397,"lastUpdatePostDateStruct":425,"startDateStruct":426,"completionDateStruct":428,"leadSponsor":430,"locationsCount":77},"100580395","at-home-genital-nerve-stimulation-for-sci-bowel-100580395","NCT06836739","At-Home Genital Nerve Stimulation for SCI Bowel","At-Home Feasibility Trial of Genital Nerve Stimulation to Modulate Neurogenic Bowel Dysfunction in Individuals Living With Spinal Cord Injury","Inclusion Criteria:\n\n1. Traumatic SCI.\n2. Minimum of 6 months' post-injury.\n3. Aged 18 years and older.\n4. Neurological level of injury T12 or higher and AIS grade A-D, as defined by the ISNCSCI.\n5. Score of 14 or higher on the ISCI BF BDS v2.1.\n6. Response to genital nerve stimulation able to be elicited upon screening.\n7. Able to understand and provide informed consent.\n\nExclusion Criteria:\n\n1. Currently enrolled in another functional electrical stimulation (FES) research trial.\n2. Females who are pregnant or planning to become pregnant in the duration of the trial (identified by self-report).\n3. Presence of a cardiac pacemaker, implanted defibrillator, or other implanted functional electrical stimulation device if, upon clinical evaluation, it may have an interaction with GNS.\n4. In the judgment of the PI and Co-Investigators, presence of medical complications that may interfere with the execution of the study.",{"count":63,"type":21},[65],"The purpose of this study is to test whether electrical stimulation of the skin in the pelvic area (near the genitals) can reduce the reflexes that cause bowel accidents in people with spinal cord injuries. Current bowel treatments either involve diet and medications or surgery. This study will evaluate whether electrical stimulation can be an alternate option for bowel management.\n\nResearchers will:\n\n* Use an FDA approved Transcutaneous Electrical Nerve Stimulation (TENS) device off-label\n* Compare a target stimulation level to a placebo stimulation level\n\nParticipants will:\n\n* Use electrical stimulation on the skin in the pelvic area for 6-8 hours each day for 4 weeks at home\n* Visit the research center 3 times to participate in exams and answer questions\n* Keep a daily diary of their bowel symptoms and stimulation times",[27],[417,418,419,420,393,394,421,422,423,424],"fecal incontinence","neurogenic bowel","tetraplegia","paraplegia","neuromodulation","bowel","feasibility","anorectal manometry",{"date":348,"type":45},{"date":427,"type":45},"2025-03-01",{"date":429,"type":21},"2026-09-30",{"name":431,"class":52},"MetroHealth Medical Center",{"id":433,"slug":434,"hasResults":12,"nctId":435,"briefTitle":436,"officialTitle":437,"acronym":438,"eligibilityCriteria":439,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":362,"enrollmentInfo":440,"targetDuration":4,"studyType":22,"phases":442,"briefSummary":443,"conditions":444,"keywords":446,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":448,"lastUpdatePostDateStruct":449,"startDateStruct":450,"completionDateStruct":451,"leadSponsor":453,"locationsCount":455},"100649463","guided-laminectomy-with-augmented-duroplasty-for-acute-traumatic-spinal-cord-injury-100649463","NCT07733401","Guided Laminectomy With Augmented Duroplasty for Acute Traumatic Spinal Cord Injury","Efficacy and Safety of Bony Decompression Combined With Dural Decompression Versus Isolated Bony Decompression for Acute Severe Traumatic Spinal Cord Injury: A Prospective, Multicenter, Randomized Controlled Trial","GLAD","Inclusion Criteria:\n\n1. Aged between 18 and 80 years old, with no restrictions on gender;\n2. Patients diagnosed with traumatic cervical or thoracic spinal cord injury (C2-T12) via clinical evaluation including medical history collection, physical examination and auxiliary imaging tests;\n3. Classified as Grade A, B or C according to the ASIA Impairment Scale (AIS) based on the International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI);\n4. Scheduled to receive surgical intervention within 72 hours after traumatic spinal cord injury;\n5. Preoperative T2-weighted MRI shows no cerebrospinal fluid signal between the spinal cord and dura mater at a minimum of one vertebral segment;\n6. Good general physical condition with an expected survival time of no less than 12 months;\n7. Voluntarily participate in this trial, sign the written informed consent form, exhibit good compliance and cooperate with all follow-up visits;\n8. Judged by attending surgeons to meet the surgical indications for posterior laminectomy and spinal internal fixation, with surgical decision-making based on surgeons' clinical experience.\n\nExclusion Criteria:\n\n1. Transverse spinal cord injury;\n2. Gunshot or penetrating sharp spinal cord injury;\n3. Pre-existing dural laceration caused by traumatic spinal cord injury;\n4. Spinal cord injury without radiographic abnormality (SCIWORA, spinal injury without fracture or dislocation);\n5. Acute exacerbation of pre-existing chronic spinal cord injury;\n6. Traumatic spinal cord injury complicated with epidural or subdural hematoma;\n7. Severe concomitant traumatic brain injury defined as a Glasgow Coma Scale (GCS) score \\\u003C 14; patients unable to follow simple verbal commands due to altered mental status; or patients with clinically significant abnormalities on cranial CT (only patients with suspected brain injury identified by investigators require cranial CT scanning);\n8. Presence of underlying comorbidities that contraindicate surgery or interfere with accurate medical and neurological assessments (judged by the principal investigator).",{"count":441,"type":21},80,[65],"The goal of this clinical trial is to learn whether expansile duraplasty can improve neurological recovery in adult patients with acute severe traumatic spinal cord injury, as well as evaluate the safety of this surgical strategy. The main questions the study aims to answer are:\n\n1. Does expansile duraplasty lead to superior motor function recovery in patients with acute severe traumatic spinal cord injury?\n2. How safe is the use of expansile duraplasty in people with acute traumatic SCI?\n\nResearchers will compare neurological function, quality of life and all safety indicators who receive expansile duraplasty to that of participants who do not receive expansile duraplasty, to determine whether the additional expansile duraplasty provides better recovery benefits for patients with traumatic spinal cord injury.\n\nParticipants will be randomly assigned to one of two groups: the laminectomy combined with expansile duraplasty group and the laminectomy-only group. All participants will complete the following procedures:\n\n1. Receive standardized spinal surgery ;\n2. Provide blood and cerebrospinal fluid samples during hospitalization;\n3. Undergo spinal computed tomography (CT) and magnetic resonance imaging (MRI) scans at baseline (pre-operation), discharge, 3 months, 6 months and 12 months after surgery;\n4. Complete standardized neurological assessments at 3, 6 and 12 months postoperatively, including ASIA motor and sensory scores, Walking Index for Spinal Cord Injury II (WISCI II), and Spinal Cord Independence Measure III (SCIM III);\n5. Fill out questionnaires at each follow-up visit, including the 36-Item Short Form Health Survey (SF-36);\n6. Be continuously monitored for all adverse events and surgical complications throughout the 12-month follow-up period.",[27,445],"Acute Spinal Cord Injury (SCI)",[447],"Acute Spinal Cord Injury","2026-07-24",{"date":373,"type":45},{"date":351,"type":21},{"date":452,"type":21},"2029-09",{"name":454,"class":52},"Xuanwu Hospital, Beijing",13,{"id":457,"slug":458,"hasResults":12,"nctId":459,"briefTitle":460,"officialTitle":461,"acronym":4,"eligibilityCriteria":462,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":362,"enrollmentInfo":463,"targetDuration":4,"studyType":22,"phases":464,"briefSummary":465,"conditions":466,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":471,"lastUpdatePostDateStruct":472,"startDateStruct":473,"completionDateStruct":475,"leadSponsor":477,"locationsCount":77},"100475403","ibci-optimization-for-veterans-with-paralysis-100475403","NCT05470478","iBCI Optimization for Veterans With Paralysis","Enhancement and Optimization of a Mobile iBCI for Veterans With Paralysis","Inclusion Criteria:\n\n* Inclusion criteria are extensive and are determined by the associated BrainGate IDE(clinicaltrials.gov # NCT00912041)\n* Informally, participants will be tetraplegic or anarthric with little or no functional use of the arms and legs\n\nExclusion Criteria:\n\n* Exclusion criteria are extensive and are determined by the associated BrainGate IDE(clinicaltrials.gov # NCT00912041).",{"count":53,"type":21},[65],"VA research has been advancing a high-performance brain-computer interface (BCI) to improve independence for Veterans and others living with tetraplegia or the inability to speak resulting from amyotrophic lateral sclerosis, spinal cord injury or stoke. In this project, the investigators enhance deep learning neural network decoders and multi-state gesture decoding for increased accuracy and reliability and deploy them on a battery-powered mobile BCI device for independent use of computers and touch-enabled mobile devices at home. The accuracy and usability of the mobile iBCI will be evaluated with participants already enrolled separately in the investigational clinical trial of the BrainGate neural interface.",[27,467,468,469,470],"Amyotrophic Lateral Sclerosis","Brain Stem Infarctions","Locked-in Syndrome","Muscular Dystrophy","2026-07-23",{"date":397,"type":45},{"date":474,"type":21},"2026-10-02",{"date":476,"type":21},"2027-06-30",{"name":103,"class":104},{"id":479,"slug":480,"hasResults":12,"nctId":481,"briefTitle":482,"officialTitle":483,"acronym":484,"eligibilityCriteria":485,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":486,"enrollmentInfo":487,"targetDuration":4,"studyType":22,"phases":488,"briefSummary":489,"conditions":490,"keywords":492,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":501,"lastUpdatePostDateStruct":502,"startDateStruct":503,"completionDateStruct":505,"leadSponsor":507,"locationsCount":77},"100611832","shoulder-health-after-rehabilitation-and-performance-training-100611832","NCT07245706","Shoulder Health After Rehabilitation and Performance Training","Ensuring Shoulder Health as a Key Factor for Long Term Health and Functioning of Manual Wheelchair Users","SHARP","Inclusion Criteria:\n\n* Persons with a paraplegia below T2\n* Manual wheelchair user\n* Age 18 - 70 years\n* At discharge from initial rehabilitation\n\nExclusion Criteria:\n\n* Trauma or surgery of the shoulder with medical indication for immobilization of more than four weeks\n* Constant use of power assistance for the wheelchair\n* Any surgical implants that exclude the participant for MRI assessments of the shoulder\n* Inability to follow the study instructions, e.g., mental health problems, language problems, dementia, claustrophobia (for MRI) etc.\n* Persons with congenital conditions leading to SCI, SCI in the context of palliative care, neurodegenerative disorders, and Guillain-Barré syndrome\n* Pregnancy","70 Years",{"count":300,"type":21},[65],"The goal of this study is to investigate the impact of a home-based shoulder strength training on the overall shoulder health in manual wheelchair users, and if the timepoint of such a training makes a difference. The study is focusing on persons with a spinal cord injury in the thoracic or lumbar region of the spine, that have only recently been injured and will soon be discharged from primary rehabilitation.\n\nThe shoulder training will take place either 3 or 12 months after discharge from primary rehabilitation and will be carried out twice a week for 12 weeks.\n\nThere are six measurements occurring every three months, which leads to an overall duration of 15 months. The measurements consist of:\n\n* Questionnaires about independence in daily life, participation, quality of life and physical activity\n* Assessment of shoulder strength, range of motion and function\n* Measurement of the daily wheelchair use during one week via sensors that are fixed to the wheelchair and wrist\n* one further questionnaire at the end of the measurement week about the occurrence of shoulder pain\n\nAdditionally, on four of the six measurement timepoints, a magnet resonance image (MRI) of the shoulder will be taken to assess the shoulder status (pathology, muscle volume and quality).\n\nThough all these measurements the researchers can additionally assess the load of daily life on the shoulders, and how well this matches the preparation during the primary rehabilitation.",[27,230,280,491],"Injury",[493,494,495,496,497,498,499,500],"Shoulder","Wheelchair","Training","Activity of Daily Life","Load","Capacity","Functioning","Monitoring","2026-07-22",{"date":471,"type":45},{"date":504,"type":45},"2026-07-16",{"date":506,"type":21},"2029-12",{"name":508,"class":509},"Swiss Paraplegic Research, Nottwil","NETWORK",{"id":511,"slug":512,"hasResults":12,"nctId":513,"briefTitle":514,"officialTitle":515,"acronym":4,"eligibilityCriteria":516,"healthyVolunteers":12,"sex":17,"minAge":517,"maxAge":518,"enrollmentInfo":519,"targetDuration":4,"studyType":22,"phases":521,"briefSummary":522,"conditions":523,"keywords":524,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":531,"lastUpdatePostDateStruct":532,"startDateStruct":533,"completionDateStruct":534,"leadSponsor":536,"locationsCount":77},"100648775","cardiovascular-autonomic-function-after-resistance-training-100648775","NCT07725952","Cardiovascular Autonomic Function After Resistance Training","Effects of 8-Week Resistance Training on Cardiovascular Autonomic Function in Spinal Cord Injury","Inclusion Criteria:\n\n* Provided written informed consent and agreed to participate in the study.\n* Adults aged 19 to 85 years.\n* Chronic spinal cord injury (SCI) of traumatic or non-traumatic etiology, at least 6 months after injury.\n* Cervical or thoracic spinal cord injury.\n* Classified as American Spinal Injury Association (ASIA) Impairment Scale (AIS) grade A, B, C, or D.\n* Sufficient upper-limb range of motion to perform resistance training.\n* Elbow extensor muscle strength of Manual Muscle Test (MMT) grade 3 or higher.\n\nExclusion Criteria:\n\n* Presence of any serious medical condition that would preclude participation in the study.\n* Inability to understand or perform the exercise program.\n* Uncontrolled diabetes mellitus or progressive neurological disease.\n* Uncontrolled hypertension (systolic blood pressure \\>140 mmHg or diastolic blood pressure \\>90 mmHg).\n* History of cardiovascular disease within the past 6 months.\n* Current use of medications that may affect heart rate variability (HRV) or baroreflex sensitivity (BRS).\n* Severe orthostatic hypotension (OH) or autonomic dysreflexia (AD).\n* Considered unsuitable for participation in the study by a board-certified specialist in Physical and Rehabilitation Medicine.","19 Years","85 Years",{"count":520,"type":21},20,[65],"The purpose of this clinical trial is to evaluate whether an 8-week upper-limb resistance training program improves cardiovascular autonomic function in adults with chronic spinal cord injury (SCI). The primary objectives are to determine whether upper-limb resistance training improves heart rate variability (HRV) and baroreflex sensitivity (BRS), and whether it improves blood pressure responses during postural change, upper-limb strength, symptoms related to orthostatic hypotension, and quality of life.\n\nParticipants will be randomly assigned to either the resistance training group or the control group. All participants will complete assessments before and after the 8-week study period, including measurements of HRV, BRS, blood pressure responses during a tilt-table test, hand grip strength, and questionnaires assessing orthostatic hypotension symptoms and quality of life. Participants assigned to the resistance training group will participate in supervised upper-limb resistance training three times per week for 8 weeks.",[27],[27,525,526,527,528,529,530],"Resistance Training","Cardiovascular Autonomic Function","Heart Rate Variability","Baroreflex Sensitivity","Orthostatic Hypotension","Exercise Rehabilitation","2026-07-21",{"date":448,"type":45},{"date":397,"type":21},{"date":535,"type":21},"2026-12-31",{"name":537,"class":52},"Pusan National University Yangsan Hospital",{"id":539,"slug":540,"hasResults":12,"nctId":541,"briefTitle":542,"officialTitle":543,"acronym":4,"eligibilityCriteria":544,"healthyVolunteers":12,"sex":17,"minAge":61,"maxAge":545,"enrollmentInfo":546,"targetDuration":4,"studyType":22,"phases":548,"briefSummary":549,"conditions":550,"keywords":551,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":555,"lastUpdatePostDateStruct":556,"startDateStruct":557,"completionDateStruct":559,"leadSponsor":561,"locationsCount":53},"100625112","exoskeletal-assisted-walking-combined-with-transcutaneous-spinal-cord-stimulation-effect-on-imaging-and-serum-biomarkers-of-skeletal-muscle-mass-and-bone-strength-100625112","NCT07418398","Exoskeletal-assisted Walking Combined With Transcutaneous Spinal Cord Stimulation: Effect on Imaging and Serum Biomarkers of Skeletal Muscle Mass and Bone Strength.","Exoskeletal-assisted Walking Combined With Transcutaneous Spinal Cord Stimulation: Effect on Imaging and Serum Biomarkers of Skeletal Muscle Mass and Bone Strength","Inclusion Criteria:\n\n* Non-walkers with an SCI greater than 3 years post injury\n* As measured by a member of the study staff, participants who have a lower extremity motor score greater or equal to 16 on the INSCSCI exam with an impairment grade of C or D\n* Neurologic level of injury as determined by study staff between C5-T10 (completed at participant's screening)\n* Capable of gripping Lofstrand crutches and\u002For a walker without assistance\n* Wheelchair reliant 100% of the time\n* Height is between 62 inches and 74 inches\n* Weight less than 220lbs\n* Anthropometric compatibility with the EAW device:\n\n  * Thigh length between 14 and 19 in (36 and 48 cm)\n  * Shank length between 17 and 22 in (43 and 55 cm)\n\nExclusion Criteria:\n\n* As determined by the study physician from the screening health exam, a history of fragility or traumatic fractures, unhealed fractures, and signs of swelling, bruising, and discoloration of the legs\n* Current bone disease diagnosis (e.g., osteomyelitis, hyperparathyroidism)\n* As determined by the study physician from the screening DXA study, a T-score at the total hip \\\u003C -3.5 or aBMD of the knee (proximal tibia and\u002For distal femur) \\\u003C 0.60 g\u002Fcm2 from the DXA screen\n* Positive pregnancy test at any of the study intervention or assessment visits, or if female participants plan to become pregnant over the course of the study, they will be excluded or withdrawn (if already enrolled) from participation\n* Currently in a gym\u002Frehabilitation program performing ambulatory interventions such as EAW, as determined by the study staff\n* Currently prescribed any medications that can affect muscle and\u002For bone metabolism, as determined by the study staff\n\nExclusion Criteria from MRI Safety Screening:\n\n* Medically unsafe to receive an MRI scan\n* Claustrophobia\n* Baclofen pump\n* Body metal, including any of the following:\n\n  * metal fragments or pieces in eyes or any other part of body\n  * pacemakers or other implanted electrical devices\n  * aneurysm clips (metal clips on wall of a large artery)\n  * metallic prostheses (metal pins and heart valves)\n  * internal hearing aids (cochlear implants)\n  * permanent eyeliner\n  * shrapnel fragments\n  * piercing that cannot be removed","60 Years",{"count":547,"type":21},24,[65],"Immobilization following spinal cord injury (SCI) results in muscle and bone loss below the level of injury, which ultimately predisposes to fracture at several sites throughout the legs and can lead to several medical complications that can devastate quality of life. There is a scarcity of research that has successfully implemented rehabilitation and\u002For exercise training interventions to preserve the musculoskeletal system during the acute phase SCI, or possibly reverse the muscle and bone loss that has already occurred in chronic SCI. This study will compare the effect of exoskeleton-assisted walking (EAW) training combined with transcutaneous spinal cord stimulation (tSCS) (EAW + active tSCS), to that of EAW + sham tSCS, on measures of muscle and bone health in a cohort of chronically injured motor incomplete SCI. A successful outcome would expand treatment options to improve musculoskeletal health over the lifetime.",[27],[27,552,261,553,554],"Transcutaneous Spinal Cord Stimulation","Exoskeleton-Assisted Walking","Muscle Cross Sectional Area","2026-07-20",{"date":501,"type":45},{"date":558,"type":21},"2026-11-01",{"date":560,"type":21},"2032-11-01",{"name":103,"class":104},{"id":563,"slug":564,"hasResults":12,"nctId":565,"briefTitle":566,"officialTitle":567,"acronym":568,"eligibilityCriteria":569,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":570,"enrollmentInfo":571,"targetDuration":4,"studyType":22,"phases":573,"briefSummary":574,"conditions":575,"keywords":576,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":578,"lastUpdatePostDateStruct":579,"startDateStruct":580,"completionDateStruct":582,"leadSponsor":584,"locationsCount":77},"100648400","a-clinical-study-of-a-fully-implanted-wireless-and-functional-bci-for-upper-limb-functional-replacement-in-tetraplegia-due-to-spinal-cord-injury-efficacy-and-safety-100648400","NCT07720882","A Clinical Study of a Fully Implanted, Wireless and Functional BCI for Upper-Limb Functional Replacement in Tetraplegia Due to Spinal Cord Injury: Efficacy and Safety","A Prospective, Multicenter, Single-Arm Target Value Clinical Trial to Evaluate the Efficacy and Safety of Implantable Brain-Computer Interface Hand Motor Function Compensation System for Upper-Limb Functional Replacement in Tetraplegic Patients With Spinal Cord Injury","\"Triple-F\" BCI","Inclusion Criteria:\n\n* 18 years ≤ age ≤ 65 years, male or female;\n* Cervical spinal cord injury (injury level C2-C6), with ASIA Impairment Scale grade A, B, or C;\n* Severe impairment of hand function on the target upper extremity: finger flexor muscle strength \\\u003C grade 3 as assessed by the ISNCSCI scale;\n* ARAT score ≥ 2 for \"hand to mouth\"; score ≥ 1 for both \"hand to top of head\" and \"hand to back of head\"; and scores ≤ 1 for each of the grasp, grip, and pinch tasks;\n* Neurological assessment confirms normal motor-related cortical function of the brain, with no acute cerebral functional changes;\n* At least 12 months have elapsed since the cervical spinal cord injury resulting in tetraplegia, and the condition has been stable for at least 6 months following standardized treatment (with documentation of rehabilitation therapy records available);\n* Good cognitive function: Mini-Mental State Examination (MMSE) score ≥ 22 and Montreal Cognitive Assessment (MoCA) score ≥ 26 ;\n* Possess the basic visual, auditory, and language comprehension abilities required for interaction, and be able to cooperate with training;\n* The subject voluntarily participates and is willing to comply with the relevant examinations and follow-up visits.\n\nExclusion Criteria:\n\n* Neurodegenerative diseases \u002F secondary injury due to tumors, or severe autonomic dysreflexia;\n* Presence of intracranial lesions or contraindications to intracranial implantation: active epilepsy or definite epileptogenic tendency; severe cerebrovascular disease; brain tumor; moderate-to-severe sequelae of traumatic brain injury; space-occupying lesions or structural abnormalities at the electrode implantation target area; already implanted with active implantable electronic devices such as cardiac pacemakers\u002Fdefibrillators, cochlear implants, deep brain stimulators, or drug infusion pumps, or presence of local metal foreign bodies\u002Fimplants in the area to be implanted; or other contraindications to intracranial implantation as assessed by the investigator;\n* Malignancies in other organ systems;\n* Cardiovascular system diseases: severe cardiac insufficiency, severe arrhythmias, or uncontrolled hypertension;\n* Other ongoing medical interventions that may affect the benefit from BCI intervention (e.g., dependence on ventilator support, tracheostomy, nasogastric tube feeding, etc.);\n* Presence of psychiatric or psychological disorders that may interfere with the subject's participation in BCI training, such as depression (HAMD ≥ 18 points) or anxiety disorder (HAMA ≥ 14 points) ;\n* Presence of active infection; severe coagulation abnormalities (activated partial thromboplastin time (APTT) or prothrombin time (PT) \\> 2.5 × upper limit of normal); or other severe systemic diseases that, as assessed by the investigator, may significantly increase surgical risk or interfere with neurological function assessment or system use;\n* Contraindications to surgery or anesthesia, or deemed unsuitable for implantation surgery by anesthesiology\u002Fsurgical assessment;\n* Fever, or vital signs and\u002For intracranial status not yet stabilized;\n* Upper-limb motor dysfunction due to other etiologies, such as amyotrophic lateral sclerosis, syringomyelia, spinal vascular diseases, muscular dystrophy, hypokalemic periodic paralysis, spondylitis, arthritis, osteomyelitis, peripheral nerve injury, tendon rupture, etc.;\n* Planned MRI examination during the device implantation period;\n* Life expectancy \\\u003C 6 months (e.g., severe end-stage diseases);\n* Participation in other drug or medical device clinical trials within the past 1 month;\n* Pregnant or breastfeeding women;\n* Other conditions that, in the investigator's judgment, make the subject unsuitable for participation in this clinical trial.","65 Years",{"count":572,"type":21},32,[65],"This prospective, multicenter, single-arm clinical trial will enroll subjects with tetraplegia secondary to spinal cord injury. An implantable brain-computer interface system for compensatory hand motor function will be used to reconstruct upper-limb function, so as to evaluate the safety and clinical efficacy of this device in achieving upper-limb functional replacement.",[27],[577,27],"BCI","2026-07-17",{"date":501,"type":45},{"date":581,"type":45},"2026-07-07",{"date":583,"type":21},"2027-04-30",{"name":585,"class":586},"NeuroXess Technology (shanghai) Co.,Ltd.","INDUSTRY",{"id":588,"slug":589,"hasResults":12,"nctId":590,"briefTitle":591,"officialTitle":592,"acronym":4,"eligibilityCriteria":593,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":594,"targetDuration":4,"studyType":22,"phases":595,"briefSummary":596,"conditions":597,"keywords":598,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":604,"lastUpdatePostDateStruct":605,"startDateStruct":607,"completionDateStruct":609,"leadSponsor":611,"locationsCount":77},"100647172","kinesio-taping-for-neurogenic-bowel-dysfunction-in-spinal-cord-injury-100647172","NCT07705984","Kinesio Taping for Neurogenic Bowel Dysfunction in Spinal Cord Injury","Effectiveness of Kinesio Taping on Neurogenic Bowel Dysfunction in Individuals With Spinal Cord Injury: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Adults aged 18 years or older with traumatic or nontraumatic spinal cord injury\n* Neurological level of injury at T12 or above\n* Upper motor neuron-type neurogenic bowel dysfunction\n* Duration of spinal cord injury longer than 6 months\n* Ability and willingness to provide written informed consent\n\nExclusion Criteria:\n\n* Age younger than 18 years\n* Neurological level of injury below T12\n* Gastrointestinal disease diagnosed before the spinal cord injury, including irritable bowel syndrome or inflammatory bowel disease\n* History of conservative treatment for neurogenic bowel dysfunction within the previous 6 months\n* Colostomy or history of bowel surgery\n* Neurological disease other than spinal cord injury that may cause gastrointestinal or anal sphincter dysfunction\n* Cognitive impairment that may interfere with participation in the study",{"count":86,"type":21},[65],"Neurogenic bowel dysfunction is a common complication of spinal cord injury and may cause constipation, difficulty with defecation, prolonged bowel care, incomplete evacuation, fecal incontinence, and reduced quality of life. This randomized controlled trial aims to evaluate the effectiveness of Kinesio Taping added to a routine bowel management program in adults with spinal cord injury and upper motor neuron-type neurogenic bowel dysfunction.\n\nThirty participants will be randomly assigned to one of two parallel groups. The control group will receive a routine bowel management program, while the intervention group will receive Kinesio Taping in addition to the routine bowel management program. Kinesio Taping will be applied to the lower abdominal and lumbosacral regions three times per week for 4 weeks.\n\nThe primary outcome will be defecation frequency recorded using a 7-day bowel diary. Secondary outcomes will include stool consistency, defecation duration, perceived constipation severity, neurogenic bowel dysfunction severity, and health-related quality of life. Assessments will be performed before and after the 4-week intervention.",[68,27],[599,600,601,602,603],"Kinesio Taping","Neurogenic Bowel","Constipation","Bowel Management","Spinal Cord Injury Rehabilitation","2026-07-10",{"date":606,"type":45},"2026-07-15",{"date":608,"type":21},"2026-07-30",{"date":610,"type":21},"2026-10-30",{"name":612,"class":52},"Pamukkale University",{"id":614,"slug":615,"hasResults":12,"nctId":616,"briefTitle":617,"officialTitle":618,"acronym":619,"eligibilityCriteria":620,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":621,"targetDuration":4,"studyType":22,"phases":622,"briefSummary":623,"conditions":624,"keywords":625,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":581,"lastUpdatePostDateStruct":631,"startDateStruct":633,"completionDateStruct":635,"leadSponsor":637,"locationsCount":77},"100585677","the-effects-of-eccentric-compared-to-standard-strength-training-in-primary-spinal-cord-injury-rehabilitation-100585677","NCT06905470","The Effects of Eccentric Compared to Standard Strength Training in Primary Spinal Cord Injury Rehabilitation","The Effects of Eccentric Compared to Standard Strength Training in Primary Spinal Cord Injury Rehabilitation - a Matched-Pair Randomized Controlled Trial","KREHA3","Inclusion Criteria:\n\n* 18 years or older.\n* informed consent as confirmed per signature.\n* traumatic or disease-related SCI.\n* participating in the routine strength training program during primary SCI rehabilitation at the study center (generally this is initiated around one month after SCI onset).\n* wheelchair dependency during activities of daily living, defined by a score of 0-2 in the SCIM subsection regarding \"Mobility in the house\".\n* passed sports medical assessment and having sufficient biceps\u002Ftriceps function to perform arm-crank training, as determined by an experienced sports medicine physician\n\nExclusion Criteria:\n\n* inflammatory or neurodegenerative diseases (including multiple sclerosis or Guillain-Barré syndrome).\n* comorbidities or other health issues that may interfere with study participation, inability or contraindications to undergo the investigated intervention.\n* MRI contraindications (magnetic metal parts or electronic implants such as pacemakers in the body).\n* pregnancy (anamnestic).",{"count":520,"type":21},[65],"The goal of this clinical trial is to assess the effects of eccentric arm-crank (KREHA) training compared to standard clinical routine strength (STAN) training in individuals undergoing primary spinal cord injury (SCI) rehabilitation.\n\nThe main questions this trail aims to answer are:\n\n* what are the effects of the training on upper body strength, aerobic performance, muscle volume, functional independence, and health-related quality of life?\n* is the KREHA training feasible to implement into the rehabilitation routine?\n\nParticipants will:\n\n* perform either 20 KREHA sessions or 20 STAN sessions within 12 weeks\n* perform a test battery to collect data on training effects before (pretest) and after (posttest) the study intervention",[27],[626,627,628,629,630],"eccentric training","strength training","upper body","aerobic performance","muscle volume",{"date":632,"type":45},"2026-07-08",{"date":634,"type":21},"2026-07",{"date":636,"type":21},"2028-07",{"name":508,"class":509},{"id":639,"slug":640,"hasResults":12,"nctId":641,"briefTitle":642,"officialTitle":643,"acronym":4,"eligibilityCriteria":644,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":645,"enrollmentInfo":646,"targetDuration":4,"studyType":22,"phases":647,"briefSummary":648,"conditions":649,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":651,"lastUpdatePostDateStruct":652,"startDateStruct":653,"completionDateStruct":655,"leadSponsor":656,"locationsCount":77},"100450242","effectiveness-of-virtual-bodily-illusion-intervention-in-upper-limb-motor-function-in-people-with-incomplete-spinal-cord-injury-100450242","NCT05142943","Effectiveness of Virtual Bodily Illusion Intervention in Upper Limb Motor Function in People With Incomplete Spinal Cord Injury.","Effectiveness of Virtual Bodily Illusion Intervention in Upper Limb Motor Function, Sensibility and Pain in People With Incomplete Spinal Cord Injury.","Inclusion Criteria:\n\n* Incomplete cervical spinal cord injury (AIS C, D or E).\n* Ability to understand instructions (Mini-Mental State Examination\\> 23 points)\n\nExclusion Criteria:\n\n* Traumatic pathology in upper limbs.\n* Other alterations of the central nervous system or peripheral\n* Alterations in the vestibular system.\n* Concomitant diseases.","99 Years",{"count":441,"type":21},[65],"Previous studies have shown that the neuroplasticity of the residual corticospinal fibers, the motor cortex and the spinal neurons plays an important role in the spontaneous functional recovery of people with neurological or musculoskeletal pathology. However, it is also possible to stimulate the neuroplasticity mechanisms of these structures through techniques aimed at rehabilitating different deficits (for example, motor function or sensitivity). In general, intervention programs are usually carried out, in most cases, using low-cost strategies such as therapeutic physical exercise programs.\n\nThe objective of this study is to analyze the effectiveness of visual illusion therapies in combination with conventional exercises on the symptoms and signs related to incomplete spinal cord injury that affects the upper limb.\n\nThe study will include the realization of three measurements that will be carried out one day before starting the program, one day after finishing it, and one month later (follow-up).\n\nThe clinical assessment will be composed of the study of the following variables: Motor function and motor skills, Upper limb isometric force, Muscle activation, Muscle tone, Quality of life, Functionality. All interventions will last eight weeks and will be planned according to the availability of volunteers. In each session, it will be recorded if any type of adverse effect occurs. There will be four types of interventions: i. Visual Illusion (IV) and therapeutic exercise program (PE), ii.placebo and PE, iii. IV, iv. IV placebo.",[650,27],"Incomplete Spinal Cord Injury","2026-07-06",{"date":581,"type":45},{"date":654,"type":45},"2021-11-01",{"date":535,"type":21},{"name":657,"class":52},"University of Valencia",{"id":659,"slug":660,"hasResults":12,"nctId":661,"briefTitle":662,"officialTitle":662,"acronym":4,"eligibilityCriteria":663,"healthyVolunteers":113,"sex":17,"minAge":18,"maxAge":486,"enrollmentInfo":664,"targetDuration":4,"studyType":22,"phases":665,"briefSummary":666,"conditions":667,"keywords":670,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":677,"lastUpdatePostDateStruct":678,"startDateStruct":680,"completionDateStruct":682,"leadSponsor":684,"locationsCount":77},"100646408","transcutaneous-spinal-electrical-stimulation-to-improve-exercise-function-after-spinal-cord-injury-100646408","NCT07692191","Transcutaneous Spinal Electrical Stimulation to Improve Exercise Function After Spinal Cord Injury.","Inclusion Criteria:\n\n* traumatic or non-traumatic spinal cord injury\n* Spinal cord injury of at least one year duration, C5 or lower, AIS A - D\n* medically stable and healthy enough to engage in and complete exercise requirements\n* willing and able to complete the exercise protocols and testing requirements\n* able to understand and follow written and verbal instructions from study staff\n* able to communicate with study staff about their exercise capabilities and preferences\n\nExclusion Criteria:\n\n* current serious injury (ies) of the upper extremities\n* known cardiovascular disease\n* unsatisfactory results of EKG screening\n* implanted electronic cardiac devices (e.g., pacemaker, defibrillator, etc.)\n* current pressure ulcer(s)\n* morbid obesity\n* known thyroid dysfunction\n* current cancer\n* current uncontrolled high blood pressure\n* uncontrolled epilepsy\n* current deep vein thrombosis\n* ventilator dependency\n* cognitive impairment",{"count":300,"type":21},[65],"Our overall objective is to decrease the prevalence of multiple sedentary-related diseases that are secondary consequences of spinal cord injury (SCI). SCI affects motor, sensory and autonomic systems and can cause very limited exercise capacity which then leads to very high rates of obesity, metabolic syndrome, type II diabetes and cardiovascular disease.\n\nThis randomized controlled study aims to determine whether and how transcutaneous spinal electrical stimulation (TSES) alters acute (immediate) exercise responses in people living with SCI. Exercise responses will be tested during incremental tests to fatigue, and during steady state tests. Testing will occur over several study visits and results will be compared within each individual as well as between groups (tetraplegia and paraplegia) and to a group of reference controls. A number of outcomes will be monitored, including whole-body metabolic responses using a metabolic cart, muscle responses using EMG sensors and muscle oxygenation using near infrared spectroscopy (NIRS) sensors, time to fatigue, power output, as well as perceptions about fatigue and effort.\n\nThe findings of this study are expected to provide evidence regarding whether and how TSES might improve acute exercise responses in people living with SCI.",[668,27,669],"Spinal Cord Injuries (SCI)","Spinal Injury",[671,37,672,673,674,675,676],"exercise","sympathetic nervous system","autonomic nervous system","arm ergometry","obesity","cardiovascular disease","2026-07-02",{"date":679,"type":45},"2026-07-09",{"date":681,"type":45},"2024-06-10",{"date":683,"type":21},"2026-10",{"name":685,"class":52},"University of Manitoba",{"id":687,"slug":688,"hasResults":12,"nctId":689,"briefTitle":690,"officialTitle":690,"acronym":4,"eligibilityCriteria":691,"healthyVolunteers":113,"sex":17,"minAge":18,"maxAge":692,"enrollmentInfo":693,"targetDuration":4,"studyType":22,"phases":694,"briefSummary":696,"conditions":697,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":699,"lastUpdatePostDateStruct":700,"startDateStruct":702,"completionDateStruct":704,"leadSponsor":706,"locationsCount":77},"100279862","phase-4-treatment-of-sleep-apnea-in-patients-with-cervical-spinal-cord-injury-100279862","NCT02922894","Treatment of Sleep Apnea in Patients With Cervical Spinal Cord Injury","Inclusion Criteria:\n\n1. healthy adults between the ages of 18 - 89\n2. chronic spinal cord injury patients (T6 and above), \\> 3 months since injury and not on mechanical ventilation, and have not received mechanical ventilation via tracheostomy in the past.\n\nExclusion Criteria:\n\n1. subjects ≤ 17 yrs old\n2. Pregnant and lactating females\n3. History of head trauma that resulted in neurological symptoms or loss of consciousness\n4. advanced heart, lung, metabolic, liver or chronic kidney disease.\n5. severe obstructive or restrictive respiratory defect by PFTs or history of tracheostomy\n6. extreme obesity defined for this protocol as BMI ≥ 40 kg\u002Fm2 (to avoid the effect of morbid obesity on ventilation).","89 Years",{"count":117,"type":21},[695],"PHASE4","This study will investigate potential therapeutic approaches for sleep-disordered breathing (SDB) in patients with chronic cervical spine injury (\\>6 months post-injury).",[698,27],"Sleep Apnea","2026-06-29",{"date":701,"type":45},"2026-07-01",{"date":703,"type":45},"2017-06-09",{"date":705,"type":21},"2027-01-30",{"name":707,"class":104},"John D. Dingell VA Medical Center",{"id":709,"slug":710,"hasResults":12,"nctId":711,"briefTitle":712,"officialTitle":713,"acronym":4,"eligibilityCriteria":714,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":715,"targetDuration":4,"studyType":22,"phases":716,"briefSummary":717,"conditions":718,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":719,"lastUpdatePostDateStruct":720,"startDateStruct":722,"completionDateStruct":724,"leadSponsor":725,"locationsCount":77},"100644900","pilot-study-exploring-the-effects-of-rhythmic-auditory-stimulation-on-gait-in-people-with-motor-incomplete-spinal-cord-injury-100644900","NCT07674927","Pilot Study Exploring the Effects of Rhythmic Auditory Stimulation on Gait in People With Motor Incomplete Spinal Cord Injury","Exploring the Effects of Rhythmic Auditory Stimulation on Gait in Motor Incomplete Spinal Cord Injury: A Pilot Study","Inclusion Criteria:\n\n* Age ≥18 years old\n* Language: English or Spanish only\n* Diagnosis: non-progressive spinal cord lesion; classification as either grade C, D, or E SCI based on American Spinal Injury Association (ASIA) Impairment Scale (AIS)\n* Able to ambulate at least a contact guard assist level\n* Time post injury: ≥6 months\n* Cadence: minimum 40 steps\u002Fminute with clear heel strike\n* Able to consent\n\nExclusion Criteria:\n\n* Individuals who use an assistive device and are unable to achieve a 2-point walking pattern (left-right-left-right) with an assistive device\n* Walks exclusively with a 3-point walking pattern with an assistive device\n* Ambulation requiring a knee-ankle-foot orthosis (KAFO)\n* Presence of additional neurological or medical processes that contribute to weakness\n* Unable to perceive music through the MedRhythyms device",{"count":364,"type":21},[65],"This pilot study aims to evaluate the feasibility and preliminary efficacy of a wearable rhythmic auditory stimulation system, MedRhythms, for improving gait parameters in patients with motor incomplete SCI. Up to 15 participants aged 18 years or older with non-progressive SCI will be enrolled. Participants will complete supervised gait training using the MedRhythms device twice weekly during regularly scheduled physical therapy sessions over a six-week period. The device uses shoe-mounted sensors and headphones to deliver real-time individualized rhythmic auditory cues based on the user's gait pattern.\n\nPrimary outcome measures include change in walking speed assessed with the 10-Meter Walk Test. Secondary outcomes include walking endurance measured by the 6-Minute Walk Test, gait parameters obtained through GAITRite analysis, and participant-reported outcomes including the Walking Index for Spinal Cord Injury II (WISCI II) and the SCI Quality of Life Satisfaction with Social Roles and Activities measure. Outcomes will be assessed at baseline, post-intervention (6 weeks), and follow-up (12 weeks).\n\nFindings from this study will provide preliminary data on the feasibility and potential clinical impact of rhythmic auditory stimulation as an adjunctive gait rehabilitation strategy for individuals with incomplete SCI.",[27],"2026-06-23",{"date":721,"type":45},"2026-06-30",{"date":723,"type":21},"2026-06-01",{"date":535,"type":21},{"name":726,"class":52},"University of California, Davis"]